Silo Pharma receives U.S. patent covering SPC-15 for stress-induced affective disorders

Silo Pharma, Inc.

USPTO issued U.S. Patent 11,491,120 for SPC-15, a prophylactic using ketamine for anxiety and PTSD in females.
Patent protects method of treatment and prevention for stress-induced affective disorders including PTSD.
Silo holds option to license assets from Columbia University including potential treatments for Alzheimer's disease.
CEO Eric Weisblum highlighted scope of allowed claims and market potential for SPC-15.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.